Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.430
+0.050 (3.62%)
At close: Nov 6, 2025, 4:00 PM EST
1.370
-0.060 (-4.20%)
After-hours: Nov 6, 2025, 7:52 PM EST
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $14.18M in the quarter ending September 30, 2025, with 710.40% growth. This brings the company's revenue in the last twelve months to $70.86M, up 1,255.21% year-over-year. In the year 2024, Lexicon Pharmaceuticals had annual revenue of $31.08M with 2,481.48% growth.
Revenue (ttm)
$70.86M
Revenue Growth
+1,255.21%
P/S Ratio
7.32
Revenue / Employee
$688,000
Employees
103
Market Cap
519.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LXRX News
- 10 hours ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 17 hours ago - Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates - GlobeNewsWire
- 2 days ago - Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans - GlobeNewsWire
- 7 days ago - Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 23 days ago - Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - GlobeNewsWire
- 6 weeks ago - Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - GlobeNewsWire
- 7 weeks ago - Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings - GlobeNewsWire